Suppr超能文献

心脏移植受者外周血中次黄嘌呤鸟嘌呤磷酸核糖转移酶(HPRT-)T细胞的频率。一种诊断同种异体移植排斥反应的非侵入性技术。

Frequency of hypoxanthine guanine phosphoribosyltransferase (HPRT-) T cells in the peripheral blood of cardiac transplant recipients. A noninvasive technique for the diagnosis of allograft rejection.

作者信息

Ansari A A, Mayne A, Sundstrom J B, Gravanis M B, Kanter K, Sell K W, Villinger F, Siu C O, Herskowitz A

机构信息

Department of Pathology, Emory University School of Medicine, Atlanta, Ga, USA.

出版信息

Circulation. 1995 Aug 15;92(4):862-74. doi: 10.1161/01.cir.92.4.862.

Abstract

BACKGROUND

Histological evaluation of serial endomyocardial biopsies performed at fixed time intervals after cardiac transplantation is the universal method used for the detection of cardiac rejection and assessment of the adequacy of antirejection therapy. No noninvasive methodology thus far investigated has achieved a high enough sensitivity and predictive accuracy to be considered as a potential replacement for endomyocardial biopsy in the detection of rejection in adults. The present study exploited the finding that the rate of spontaneous mutation in the hypoxanthine guanine phosphoribosyltransferase (HPRT) gene is higher in proliferating human T cells than in resting cells. Thus, it was reasoned that in the posttransplantation setting, the frequency of HPRT- cells in peripheral blood may provide an indirect measure of alloactivated T lymphocytes.

METHODS AND RESULTS

This study consisted of determining the clonal frequency of HPRT- mutant cells (FMC/10(6) peripheral blood mononuclear cells [PBMCs]) within a total of 293 peripheral blood samples representing various numbers of sequential samples from each of 27 transplant recipients. These sequential samples represented time periods when endomyocardial biopsy specimens showed either (1) no evidence of rejection (n = 5 patients), (2) a single initial episode after transplantation of early (< 1 year) or late (> 1 year) rejection (n = 12 patients), or (3) multiple rejection episodes (n = 10 patients). Statistical analyses were used to quantify the time profiles of FMC/10(6) PBMCs in serial samples among transplant recipients and to determine the association of these profiles with both the onset of first rejection episodes and, in appropriate patients, the recurrence of rejection episodes. Data showed that PBMCs from patients with no evidence of rejection uniformly gave low values of < 6 FMC/10(6) cells, a frequency similar to that seen in healthy nontransplanted volunteers. In contrast, 19 of the 22 PBMC samples that were obtained from patients whose corresponding biopsy sample was diagnosed with a histological rejection grade of > or = 3 gave values of > 6 FMC/10(6) cells, 11 of which gave values > 50/10(6) cells (range, 146 to 46,982 FMC/10(6) cells). A significant association between the onset of first rejection and an increased rate of FMC/10(6) values was noted (P = .0001). The ability of a rising trend in FMC/10(6) values to correctly identify the onset of rejection was 81.8% and to correctly identify no rejection, 100%. In addition, a significant association between recurrent rejection episodes and persistence of high FMC/10(6) values in the weeks after treated rejection episodes was noted (P = .0003). The ability of a persistently elevated trend in values of FMC/10(6) cells to correctly identify recurrent rejection was 90% and to correctly identify no rejection, 100%.

CONCLUSIONS

Increasing frequencies of HPRT- mutant cells in peripheral blood correlated with the onset of first rejection, and persistently elevated HPRT- mutant cells in the weeks after a treated rejection episode correlated with recurrent rejection. This quantitative noninvasive assay may thus serve as a useful adjunct to endomyocardial biopsy for monitoring post-cardiac transplantation patients, and its use as a prospective diagnostic tool merits further study.

摘要

背景

心脏移植后按固定时间间隔进行系列心内膜心肌活检的组织学评估是用于检测心脏排斥反应及评估抗排斥治疗是否充分的通用方法。迄今为止,尚未有任何一种已研究的非侵入性方法能达到足够高的敏感性和预测准确性,从而被视为可替代心内膜心肌活检用于检测成人排斥反应的潜在方法。本研究利用了这样一个发现,即次黄嘌呤鸟嘌呤磷酸核糖转移酶(HPRT)基因的自发突变率在增殖的人T细胞中高于静止细胞。因此,据推测在移植后的情况下,外周血中HPRT -细胞的频率可能提供同种异体激活的T淋巴细胞的间接测量指标。

方法与结果

本研究包括确定293份外周血样本中HPRT -突变细胞的克隆频率(FMC/10⁶外周血单个核细胞[PBMC]),这些样本来自27名移植受者,每个受者有不同数量的系列样本。这些系列样本代表了心内膜心肌活检标本显示以下情况的时间段:(1)无排斥反应证据(5例患者);(2)移植后早期(<一年)或晚期(>一年)首次出现单次排斥发作(12例患者);或(3)多次排斥发作(10例患者)。采用统计分析来量化移植受者系列样本中FMC/10⁶PBMC的时间变化情况,并确定这些变化情况与首次排斥发作的开始以及在合适患者中排斥发作的复发之间的关联。数据显示,无排斥反应证据的患者的PBMC一致给出低于6 FMC/10⁶细胞的低值,这一频率与健康未移植志愿者中所见相似。相比之下,从相应活检样本被诊断为组织学排斥分级≥3级的患者中获得的22份PBMC样本中有19份给出的值>6 FMC/10⁶细胞,其中11份给出的值>50/10⁶细胞(范围为146至46,982 FMC/10⁶细胞)。首次排斥发作的开始与FMC/10⁶值的增加率之间存在显著关联(P = .0001)。FMC/10⁶值上升趋势正确识别排斥发作开始的能力为81.8%,正确识别无排斥反应的能力为100%。此外,在治疗后的排斥发作后数周内,排斥发作复发与高FMC/10⁶值的持续存在之间存在显著关联(P = .0003)。FMC/10⁶细胞值持续升高趋势正确识别排斥复发的能力为90%,正确识别无排斥反应的能力为100%。

结论

外周血中HPRT -突变细胞频率的增加与首次排斥发作的开始相关,治疗后的排斥发作后数周内HPRT -突变细胞持续升高与排斥复发相关。因此,这种定量非侵入性检测方法可作为心内膜心肌活检的有用辅助手段,用于监测心脏移植后患者,将其用作前瞻性诊断工具值得进一步研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验